SAMSUNG BIOLOGICS Co., Ltd.(KR:207940)
â‚©1,375,000.00+9000.00 (+0.66%)
KR:207940
SAMSUNG BIOLOGICS Co., Ltd. financials statements
â‚©1,375,000.00
At close:+9000.00 (+0.66%)
Want to see KR:207940 full AI Analyst Report?
SAMSUNG BIOLOGICS Co., Ltd. (207940) Ratios
1 Followers
SAMSUNG BIOLOGICS Co., Ltd. Ratios
KR:207940's free cash flow for Q2 2026 was ₩537.37B. For the 2026 fiscal year, KR:207940's free cash flow was decreased by ₩-87.43B and operating cash flow was ₩624.80B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.74 | 1.03 | 1.33 | 1.54 | 2.55 |
| Quick Ratio | 0.90 | 0.50 | 0.69 | 0.98 | 1.63 |
| Cash Ratio | 0.06 | 0.07 | 0.09 | 0.21 | 0.04 |
| Solvency Ratio | 0.67 | 0.26 | 0.22 | 0.15 | 0.19 |
| Operating Cash Flow Ratio | 0.89 | 0.31 | 0.40 | 0.23 | 0.41 |
| Short-Term Operating Cash Flow Coverage | 7.03 | 5.07 | 1.20 | 0.84 | 2.84 |
| Net Current Asset Value | â‚© 798.74B | â‚© -913.50B | â‚© -693.72B | â‚© -1.14T | â‚© -155.73B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.08 | 0.09 | 0.12 | 0.15 | 0.16 |
| Debt-to-Equity Ratio | 0.12 | 0.14 | 0.19 | 0.28 | 0.26 |
| Debt-to-Capital Ratio | 0.11 | 0.12 | 0.16 | 0.22 | 0.21 |
| Long-Term Debt-to-Capital Ratio | 0.07 | 0.08 | 0.02 | 0.10 | 0.18 |
| Financial Leverage Ratio | 1.48 | 1.59 | 1.63 | 1.85 | 1.60 |
| Debt Service Coverage Ratio | 6.53 | 4.48 | 0.91 | 0.90 | 3.04 |
| Interest Coverage Ratio | 70.93 | 26.40 | 13.65 | 15.35 | 36.53 |
| Debt to Market Cap | 0.01 | 0.02 | 0.03 | 0.04 | 0.02 |
| Interest Debt Per Share | 20704.54 | 33187.81 | 43008.99 | 56832.60 | 30063.34 |
| Net Debt to EBITDA | 0.28 | 0.54 | 0.96 | 1.26 | 1.78 |
| Profitability Margins | |||||
| Gross Profit Margin | 54.52% | 48.08% | 47.93% | 48.04% | 50.06% |
| EBIT Margin | 47.13% | 41.03% | 30.14% | 32.77% | 34.27% |
| EBITDA Margin | 61.04% | 58.16% | 43.40% | 43.04% | 44.59% |
| Operating Profit Margin | 45.41% | 37.78% | 30.14% | 32.77% | 34.27% |
| Pretax Profit Margin | 46.49% | 39.60% | 30.31% | 33.62% | 35.80% |
| Net Profit Margin | 39.16% | 30.98% | 23.21% | 26.59% | 25.10% |
| Continuous Operations Profit Margin | 35.43% | 29.75% | 23.21% | 26.59% | 25.10% |
| Net Income Per EBT | 84.22% | 78.23% | 76.58% | 79.09% | 70.12% |
| EBT Per EBIT | 102.39% | 104.81% | 100.57% | 102.58% | 104.46% |
| Return on Assets (ROA) | 16.13% | 6.25% | 5.35% | 4.81% | 4.94% |
| Return on Equity (ROE) | 23.95% | 9.93% | 8.72% | 8.88% | 7.89% |
| Return on Capital Employed (ROCE) | 24.26% | 11.02% | 9.37% | 7.93% | 7.83% |
| Return on Invested Capital (ROIC) | 17.81% | 7.97% | 6.36% | 5.69% | 5.36% |
| Return on Tangible Assets | 16.22% | 9.20% | 8.40% | 7.51% | 4.96% |
| Earnings Yield | 2.28% | 1.60% | 1.53% | 1.38% | 0.65% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.84 | 2.81 | 4.97 | 3.66 | 3.64 |
| Payables Turnover | 34.65 | 10.20 | 9.24 | 26.16 | 24.28 |
| Inventory Turnover | 0.97 | 0.64 | 0.73 | 0.66 | 0.77 |
| Fixed Asset Turnover | 0.75 | 0.60 | 0.85 | 0.78 | 0.70 |
| Asset Turnover | 0.41 | 0.20 | 0.23 | 0.18 | 0.20 |
| Working Capital Turnover Ratio | 2.57 | 4.56 | 2.03 | 1.50 | 1.09 |
| Cash Conversion Cycle | 426.78 | 660.92 | 535.00 | 641.83 | 557.25 |
| Days of Sales Outstanding | 62.48 | 130.12 | 73.37 | 99.74 | 100.15 |
| Days of Inventory Outstanding | 374.83 | 566.58 | 501.14 | 556.04 | 472.13 |
| Days of Payables Outstanding | 10.53 | 35.78 | 39.52 | 13.95 | 15.03 |
| Operating Cycle | 437.31 | 696.70 | 574.52 | 655.78 | 572.28 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 48611.75 | 35844.02 | 35994.65 | 21009.36 | 10452.89 |
| Free Cash Flow Per Share | 18513.55 | 6086.06 | 12116.91 | -1238.41 | 769.01 |
| Dividend Paid and CapEx Coverage Ratio | 1.62 | 1.20 | 1.51 | 0.94 | 1.08 |
| Capital Expenditure Coverage Ratio | 1.62 | 1.20 | 1.51 | 0.94 | 1.08 |
| Operating Cash Flow Coverage Ratio | 2.42 | 1.12 | 0.87 | 0.38 | 0.35 |
| Operating Cash Flow to Sales Ratio | 0.49 | 0.47 | 0.45 | 0.32 | 0.29 |
| Free Cash Flow Yield | 1.09% | 0.42% | 1.00% | -0.10% | 0.06% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 43.93 | 62.35 | 65.47 | 72.28 | 153.41 |
| Price-to-Sales (P/S) Ratio | 17.20 | 19.31 | 15.20 | 19.22 | 38.51 |
| Price-to-Book (P/B) Ratio | 10.52 | 6.19 | 5.71 | 6.42 | 12.10 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 91.55 | 239.75 | 100.12 | -1026.76 | 1805.42 |
| Price-to-Operating Cash Flow Ratio | 34.87 | 40.71 | 33.70 | 60.52 | 132.82 |
| Price-to-Earnings Growth (PEG) Ratio | 0.68 | 2.37 | 12.31 | 0.77 | 2.42 |
| Enterprise Value Multiple | 28.46 | 33.75 | 35.98 | 45.90 | 88.15 |
| Enterprise Value | 79.16T | 68.64T | 57.70T | 59.30T | 61.63T |
| EV to EBITDA | 28.46 | 33.75 | 35.98 | 45.90 | 88.15 |
| EV to Sales | 17.37 | 19.63 | 15.62 | 19.76 | 39.30 |
| EV to Free Cash Flow | 92.46 | 243.63 | 102.87 | -1055.65 | 1842.66 |
| EV to Operating Cash Flow | 35.21 | 41.37 | 34.63 | 62.23 | 135.56 |
| Tangible Book Value Per Share | 159838.18 | 115343.66 | 86375.41 | 66643.91 | 114024.62 |
| Shareholders’ Equity Per Share | 161139.94 | 235567.95 | 212362.93 | 198057.32 | 114764.36 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.24 | 0.25 | 0.23 | 0.21 | 0.30 |
| Revenue Per Share | 98550.43 | 75546.99 | 79812.25 | 66161.74 | 36054.42 |
| Net Income Per Share | 38588.93 | 23402.30 | 18528.25 | 17592.67 | 9050.11 |
| Tax Burden | 0.84 | 0.78 | 0.77 | 0.79 | 0.70 |
| Interest Burden | 0.99 | 0.97 | 1.01 | 1.03 | 1.04 |
| Research & Development to Revenue | 0.01 | 0.01 | 0.02 | 0.05 | 0.05 |
| SG&A to Revenue | 0.08 | 0.09 | 0.15 | 0.10 | 0.11 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.39 | 1.53 | 1.94 | 1.19 | 1.16 |
Currency in KRW

